Morgan Stanley
BDTX icon

Morgan Stanley’s Black Diamond Therapeutics BDTX Stock Holding History

Morgan Stanley’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$189K Sell
88,623
-6,526
-7% -$15.5K ﹤0.01% 5901
2025
Q4 		$231K Buy
95,149
+26,011
+38% +$92.1K ﹤0.01% 5876
2025
Q3 		$262K Sell
69,138
-21,180
-23% -$62K ﹤0.01% 5783
2025
Q2 		$224K Sell
90,318
-334,042
-79% -$644K ﹤0.01% 5805
2025
Q1 		$658K Buy
424,360
+206,340
+95% +$433K ﹤0.01% 5206
2024
Q4 		$467K Buy
218,020
+93,016
+74% +$267K ﹤0.01% 5442
2024
Q3 		$544K Sell
125,004
-91,324
-42% -$497K ﹤0.01% 5364
2024
Q2 		$1.01M Buy
216,328
+157,430
+267% +$845K ﹤0.01% 4956
2024
Q1 		$299K Buy
58,898
+35,236
+149% +$142K ﹤0.01% 5563
2023
Q4 		$66.5K Buy
23,662
+1,611
+7% +$3.78K ﹤0.01% 6295
2023
Q3 		$63.3K Buy
22,051
+5,782
+36% +$21.3K ﹤0.01% 6066
2023
Q2 		$82.2K Sell
16,269
-11,705
-42% -$23.9K ﹤0.01% 6029
2023
Q1 		$52.9K Sell
27,974
-3,228
-10% -$7.42K ﹤0.01% 6269
2022
Q4 		$56.2K Sell
31,202
-197,987
-86% -$357K ﹤0.01% 6240
2022
Q3 		$387K Sell
229,189
-307,031
-57% -$947K ﹤0.01% 5392
2022
Q2 		$1.32M Buy
536,220
+42,858
+9% +$99.6K ﹤0.01% 4832
2022
Q1 		$1.37M Sell
493,362
-280,574
-36% -$1.02M ﹤0.01% 4780
2021
Q4 		$4.13M Buy
773,936
+12,845
+2% +$89.7K ﹤0.01% 3917
2021
Q3 		$6.44M Buy
761,091
+160,071
+27% +$1.58M ﹤0.01% 3412
2021
Q2 		$7.33M Buy
601,020
+588,232
+4,600% +$11.6M ﹤0.01% 3361
2021
Q1 		$311K Sell
12,788
-98,873
-89% -$2.67M ﹤0.01% 5400
2020
Q4 		$3.58M Buy
111,661
+103,150
+1,212% +$3.39M ﹤0.01% 3622
2020
Q3 		$257K Buy
8,511
+4,695
+123% +$143K ﹤0.01% 4974
2020
Q2 		$161K Buy
3,816
+2,406
+171% +$88.6K ﹤0.01% 5179
2020
Q1 		$35K Buy
+1,410
New +$42.9K ﹤0.01% 5588

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Morgan Stanley's BDTX Position: Q1 2026 in Review

Morgan Stanley reduced its Black Diamond Therapeutics (BDTX) stake by 6.9% in Q1 2026, selling an estimated $15.5K and leaving 88,623 shares worth $189K. The position accounts for ﹤0.01% of the portfolio, ranked #5901.

Morgan Stanley first reported a position in BDTX in Q1 2020 and has held it in 25 quarters since. The position peaked at $7.33M in Q2 2021. 104 funds tracked by Wall St. Rank hold BDTX as of Q1 2026.

  • Morgan Stanley held 88,623 shares of Black Diamond Therapeutics worth $189K as of Q1 2026.
  • Morgan Stanley sold 6,526 Black Diamond Therapeutics shares in Q1 2026, an estimated $15.5K.
  • Black Diamond Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #5901 holding.
  • Morgan Stanley first reported a position in Black Diamond Therapeutics in Q1 2020 and has held it in 25 quarters since.
  • Morgan Stanley's Black Diamond Therapeutics position peaked at $7.33M in Q2 2021.
  • 104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.